AQST vs DARE vs NKTR vs PRGO

For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.

8% revenue growth year-over-year, versus -99. 7% for Daré Bioscience, Inc. (DARE). Analysts rate Aquestive Therapeutics, Inc. (AQST) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Aquestive Therapeutics, Inc.

(AQST) delivered a total return of +23. 7%, compared to -82. 4% for Daré Bioscience, Inc. (DARE). Over 10 years, the gap is even starker: NKTR returned -59. 1% versus DARE's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Daré Bioscience, Inc.

(DARE) is the lower-risk stock at 0. 48β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 286% more volatile than DARE relative to the S&P 500. On balance sheet safety, Perrigo Company plc (PRGO) carries a lower debt/equity ratio of 135% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.

8% versus -99. 7% for Daré Bioscience, Inc. (DARE). On earnings-per-share growth, the picture is similar: Daré Bioscience, Inc. grew EPS 88. 4% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PRGO leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Perrigo Company plc (PRGO) is the more profitable company, earning -33.

5% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps -33. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AQST: 112.

8% to $9. 00.

In this comparison, PRGO (9.

8% yield) pays a dividend. AQST, DARE, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Daré Bioscience, Inc.

(DARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48)). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DARE: -99. 0%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AQST is a small-cap quality compounder stock; DARE is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while AQST, DARE, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.